China regulators launch a review for BeiGene’s PD-1; PureTech co-founder hops to Longwood Fund
→ Beijing-based BeiGene says that China’s regulatory group — the National Medical Products Administration of China — has accepted its NDA for their PD-1 checkpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
